Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab

被引：63

作者：

Schmidt, E

Herzog, S

Bröcker, EB

Zillikens, D

Goebeler, M ^{[1
]}

机构：

[1] Univ Wurzburg, Dept Dermatol, D-97080 Wurzburg, Germany

[2] Univ Hosp Schleswig Holstein, Dept Dermatol, D-23538 Lubeck, Germany

[3] Heidelberg Univ, Med Ctr Mannheim, D-68135 Mannheim, Germany

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2005年 / 153卷 / 02期

关键词：

D O I：

10.1111/j.1365-2133.2005.06740.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：449 / 451

页数：4

共 11 条

[1] Mechanism of action of rituximab [J].

Cerny, T ;

Borisch, B ;

Introna, M ;

Johnson, P ;

Rose, AL .

ANTI-CANCER DRUGS, 2002, 13 :S3-S10

[2] Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis [J].

Edwards, JCW ;

Szczepanski, L ;

Szechinski, J ;

Filipowicz-Sosnowska, A ;

Emery, P ;

Close, DR ;

Stevens, RM ;

Shaw, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2572-2581

[3]

Goebeler Matthias, 2004, J Dtsch Dermatol Ges, V2, P774, DOI 10.1046/j.1439-0353.2004.04702.x-i1

[4] Guidelines for the management of pemphigus vulgaris [J].

Harman, KE ;

Albert, S ;

Black, MM .

BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (05) :926-937

[5] Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab) [J].

Herrmann, G ;

Engert, A ;

Hunzelmann, N .

BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (03) :602-603

[6]

Ishii K, 1997, J IMMUNOL, V159, P2010

[7] Anti B cell therapy (rituximab) in the treatment of autoimmune diseases [J].

Kazkaz, H ;

Isenberg, D .

CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (04) :398-402

[8] Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia [J].

Lim, SH ;

Zhang, Y ;

Wang, Z ;

Esler, WV ;

Beggs, D ;

Pruitt, B ;

Hancock, P ;

Townsend, M .

BONE MARROW TRANSPLANTATION, 2005, 35 (02) :207-208

[9] Treatment of childhood autoimmune haemolytic anaemia with rituximab [J].

Quartier, P ;

Brethon, B ;

Philippet, P ;

Landman-Parker, J ;

Le Deist, F ;

Fischer, A .

LANCET, 2001, 358 (9292) :1511-1513

[10] Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder [J].

Salopek, TG ;

Logsetty, S ;

Tredget, EE .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (05) :785-788

← 1 2 →